Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

oncoReveal™ Core LBx

oncoReveal™ Core LBx

›

MLL2 mutation	HER2 Positive Breast Cancer	MLL2 mutation	HER2 Positive Breast Cancer	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3
MLL2 mutation + Chr del(8p)	Chronic Lymphocytic Leukemia	MLL2 mutation + Chr del(8p)	Chronic Lymphocytic Leukemia	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
MLL2 mutation	Solid Tumor	MLL2 mutation	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MLL2 mutation	Non Small Cell Lung Cancer	MLL2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MLL2 mutation	Prostate Cancer	MLL2 mutation	Prostate Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
TMB-H + MLL2 mutation	Urothelial Cancer	TMB-H + MLL2 mutation	Urothelial Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3